• Even the most competent physician can be prone to misusing epidemiologic concepts. An example of inaccurate decision making, resting on Bayes’s theorem, occurred in a recent study in which primary care physicians were given clinical scenarios. Although the clinicians confidently provided their estimates of the probabilities of given disorders, no consensus could be found among the estimates. Another study assessed the ability of medical students, residents, and attending physicians to correctly determine the positive predictive value of a hypothetical screening test. The vast majority of respondents not only got the question wrong but also had an answer that would have led to the opposite clinical conclusions, guessing an incorrect positive predictive value of 95% when the true answer was 2%.

• Clinical gestalt can also accurately assess the pretest probability of PE.
• For patients with a low pretest probability of PE, the Pulmonary Embolism Rule-out Criteria can be used to rule out PE without further testing including no need to order a
• D-dimer.
• The YEARS protocol may be used to exclude a subset of patients from having a workup to rule out PE when their D-dimer is less than 1000 as opposed to 500.
• Novel or new oral anticoagulants are becoming the mainstay of treatment for the hemodynamically stable patient with PE.
• Intravenous alteplase, catheter-directed thrombolysis, surgical embolectomy, and catheter-directed embolectomy are treatment modalities for patients with PE who are hemodynamically unstable.
• For patients in imminent or actual PE-related cardiac arrest, current guidelines recommend a bolus regimen consisting of 50 mg IV t-PA given over two minutes and repeated after 15 minutes in the absence of return of spontaneous circulation.
• A subset of patients with PE can be treated as outpatients if their Simplified Pulmonary Severity Index is 0.

Lymphocyte immunophenotyping by flow cytometry can distinguish between malignant (clonal) and nonmalignant (nonclonal) causes of lymphocytosis and eliminates the need to rely on the duration or magnitude of the lymphocyte count elevation to differentiate CLL and other lymphoproliferative disorders from reactive causes of lymphocytosis.

Chromosome analysis by FISH predicts patient survival. In a retrospective analysis of a heterogeneous patient population, many of whom had advanced-stage disease and were previously treated, Dohner and colleagues developed a hierarchical system that assigns patients to one of five categories with widely different median survival.

The development and therapeutic application of anti-CD20 monoclonal antibodies in the 1990s revolutionized the care of patients with lymphoid malignancy. Several trials evaluated the efficacy of combining monoclonal antibodies with chemotherapy (CIT) for patients with CLL.

• Lymphocyte immunophenotyping by flow cytometry can distinguish between malignant (clonal) and nonmalignant (nonclonal) causes of lymphocytosis and eliminates the need to rely on the duration or magnitude of the lymphocyte count elevation to differentiate CLL and other lymphoproliferative disorders from reactive causes of lymphocytosis.
• Chromosome analysis by FISH predicts patient survival. In a retrospective analysis of a heterogeneous patient population, many of whom had advanced-stage disease and were previously treated, Dohner and colleagues developed a hierarchical system that assigns patients to one of five categories with widely different median survival.
• The development and therapeutic application of anti-CD20 monoclonal antibodies in the 1990s revolutionized the care of patients with lymphoid malignancy. Several trials evaluated the efficacy of combining monoclonal antibodies with chemotherapy (CIT) for patients with CLL.

• CT of the chest has taken a greater role in determining injury severity in inhalation injury.
• Airway control and ventilator management remain the mainstays of treatment in those with severe injury.
• Volumetric diffusive respiration is a mode specifically developed for inhalation injury that has been shown to decrease use of other rescue modes of ventilation.

• Lymphocyte immunophenotyping by flow cytometry can distinguish between malignant (clonal) and nonmalignant (nonclonal) causes of lymphocytosis and eliminates the need to rely on the duration or magnitude of the lymphocyte count elevation to differentiate CLL and other lymphoproliferative disorders from reactive causes of lymphocytosis.
• Chromosome analysis by FISH predicts patient survival. In a retrospective analysis of a heterogeneous patient population, many of whom had advanced-stage disease and were previously treated, Dohner and colleagues developed a hierarchical system that assigns patients to one of five categories with widely different median survival.
• The development and therapeutic application of anti-CD20 monoclonal antibodies in the 1990s revolutionized the care of patients with lymphoid malignancy. Several trials evaluated the efficacy of combining monoclonal antibodies with chemotherapy (CIT) for patients with CLL.

• Members of the European Organisation for Research and Treatment of Cancer–Invasive Fungal Infection Cooperative Group and National Institute of Allergy and Infectious Diseases Mycoses Study Group formed a consensus committee to develop standard definitions for invasive fungal infections for clinical research.
• The development of standardized methodology for antifungal susceptibility testing is another recent advance in the laboratory evaluation of Aspergillus species. Although azole resistance by Aspergillus species is unusual, patients exposed chronically to antifungal triazoles have been reported to have refractory infection caused by isolates with elevated minimum inhibitory concentrations.
• Fusarium and Scedosporium species are increasingly common causes of infections in surgical patients, especially in recipients of stem cell or organ transplants.

• Topical therapy is the mainstay of treatment for psoriasis, particularly in mild cases. Topical corticosteroids are the most commonly prescribed class of medication but are now often used together with topical calcipotriene, a vitamin D3 analogue, or topical tazarotene, a retinoid; both calcipotriene and tazarotene were approved by the Food and Drug Administration (FDA) for the treatment of psoriasis.
• Emollients are an important part of any topical regimen for psoriasis. Application of petrolatum alone may be sufficient therapy for some patients. More elegant creams and lotions are helpful but are somewhat less effective than greasy ointments. Tar and salicylic acid shampoos are valuable in the treatment of patients with scalp involvement. These preparations are available without prescription.
• Short-term use of the antimetabolite methotrexate can be an extremely effective treatment of psoriasis. Methotrexate is indicated for patients who do not respond adequately to phototherapy and for patients with psoriatic arthritis. The source of methotrexate’s efficacy against psoriasis was once thought to be its antimitotic effect on proliferating macrophages and T cells.